Company calls BIOLASE Website Representations False and Misleading

Company calls BIOLASE Website Representations False and Misleading 
CERRITOS, CA -- (Marketwired) -- 03/24/14 --  Millennium Dental
Technologies Inc. (MDT) -- the world leader in dentist satisfaction
of its signature value propositions LANAP(R) and LAPIP(TM) protocols
-- has issued comments regarding false and misleading representations
made by Biolase Inc. regarding a former MDT management level
employee. The company considers the statements made by Biolase
regarding MDT former vice president of global sales and marketing,
Brian Jaffe, to be false and misleading.  
Biolase has published on its website the following representation,
"Prior to joining Biolase, Jaffe served as vice president of global
sales at Millennium Dental Technologies during 2013, growing the
periodontal laser sales reach by realigning and expanding the U.S.
sales force and expanding international distribution." 
Robert H. Gregg, DDS, co-founder and president of Millennium Dental
Technologies stated, "Jaffe did very little that could be considered
growing the periodontal laser sales reach of the LANAP(R) protocol
for periodontitis treatment, or the LAPIP(TM) protocol for treating
ailing and failing implants." Dr. Gregg said, "In fact, Jaffe was a
block in the process of growing our domestic sales, as indicated by
the poor sales results compared to the prior year." 
Delwin K. McCarthy, DDS, chief technology officer and co-founder of
Millennium Dental Technologies stated, "Brian is a really neat guy,
but unfortunately, even with bringing two independent sales reps on
board, his actions did nothing to realign or expand sales within our
U.S. sales force. The reality is sales slightly contracted under his
Mark Monaghan, MDT CEO commented, "It is simply not true that Brian
Jaffe did anything to expand international distribution." Monaghan
continued, "Brian's past experience included broad international
distribution and we were hoping that he would do the same for MDT.
Unfortunately, in the short six months of his tenure with us, he had
no impact on international sales including lack of follow-up with
existing international resellers."  
Dr. Gregg added, "Jaffe fought and resisted key marketing and pricing
initiatives, which ultimately resulted in his departure. But he does
have a noteworthy tennis forehand." Dr. Gregg quipped. 
NOTE TO EDITORS: Additional information can be viewed at  
Mark Monaghan
Dr. Delwin McCarthy
Chief Technology Officer
Dr. Robert Gregg
Press spacebar to pause and continue. Press esc to stop.